Skip to main content
CAMBIUM BIO LIMITED logo

CAMBIUM BIO LIMITED — Investor Relations & Filings

Ticker · CMB ISIN · AU0000327769 ASX Professional, scientific and technical activities
Open in API
Filings indexed 504 across all filing types
Latest filing 2017-11-01 AGM Information
Country AU Australia
Listing ASX CMB

About CAMBIUM BIO LIMITED

https://www.cambium.bio

Cambium Bio Limited is a clinical-stage regenerative medicine company focused on developing innovative cellular therapies to treat unmet medical needs in ophthalmology and inflammatory diseases. The company's primary focus is on its lead candidate, EluRegen, a first-in-class topical biologic designed for the treatment of corneal epithelial defects and dry eye disease. Utilizing its proprietary technology platforms, the company aims to harness the regenerative potential of biologics to provide effective treatments for chronic conditions. In addition to its ophthalmic pipeline, the company maintains assets in the field of mesenchymal stem cell therapies, including Progenza, which targets osteoarthritis and neuropathic pain. The company emphasizes a data-driven approach to clinical development, seeking to improve patient outcomes through advanced tissue engineering and cell-based solutions.

Recent filings

Filing Released Lang Actions
Chairman's Address to Shareholders 3 pages 211.5KB
AGM Information Classification · 95% confidence The document is titled '2017 Annual General Meeting Chairman’s Address' and is an ASX announcement dated 2 November 2017. It contains the Chairman's speech and references to presentations by the CEO that were lodged separately on the ASX announcements platform prior to the meeting. The content focuses on the progress and achievements of the company over the past year, updates on clinical trials, collaborations, intellectual property, and financial highlights. It is clearly a speech delivered at the Annual General Meeting (AGM) and not a full annual report or financial statement. The document length is 7943 characters, which is consistent with a detailed AGM address but not a full report. There is no indication that this document is a report publication announcement or a regulatory filing. Therefore, the document fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the AGM, such as the Chairman's address.
2017-11-01 English
CEO Presentation to 2017 Annual General Meeting 35 pages 4.7MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation dated November 2, 2017, containing business highlights, financial highlights for FY17, development pipeline, collaboration details, trial results, and strategic outlook. It includes forward-looking statements, an agenda, and extensive discussion of clinical trials and business updates. The content is structured as a presentation aimed at investors or stakeholders, focusing on financials, strategy, and market position rather than a formal regulatory filing or full annual report. There is no indication that this is a full Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is not a transcript of a call, nor an audit or legal report. The presence of slides, forward-looking statements, and business updates strongly suggests this is an Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2017-11-01 English
Results of Annual General Meeting 2 pages 866.0KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Results of Annual General Meeting Held 2 November 2017' and provides detailed voting results for resolutions passed at the AGM, including adoption of the remuneration report, re-election of directors, and approval of additional placement capacity. It references compliance with Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001, which govern disclosure of voting results. The document is short (3332 characters) and focuses solely on the voting outcomes rather than the meeting materials or the full AGM report. Therefore, it is best classified as a Declaration of Voting Results & Voting Rights Announcements (DVA).
2017-11-01 English
Presentation on Japan First Strategy at Ord Minnett 21 pages 3.9MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation dated November 1, 2017, focusing on the company's technology platform, development pipeline, clinical trial results, and strategic outlook, particularly related to regenerative medicine and stem cell therapies. It contains forward-looking statements, company snapshot, product development details, clinical trial design and results, and market strategy. The content is structured as a presentation with slides and images (omitted here), typical of investor or corporate presentations. There is no indication that this is a formal regulatory filing like an annual or interim report, audit report, or earnings release. It is not a transcript of a call, nor a voting result or legal proceeding. The document is too long and detailed to be a simple announcement or report publication notice. The presence of forward-looking statements and detailed business and clinical information aligns with an Investor Presentation (IP).
2017-10-31 English
Appendix 4C - Quarterly 6 pages 1.2MB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly results for the period ended 30 September 2017' and includes detailed financial data such as cash flow statements, operating cash inflows and outflows, and estimated cash outflows for the next quarter. It references Appendix 4C, which is a quarterly cash flow report required by the ASX Listing Rules. The document contains substantive financial data for a quarter, including cash flow from operating, investing, and financing activities, as well as reconciliations and notes on payments to directors and related parties. This matches the definition of an Interim / Quarterly Report (IR), which must contain actual financial statements or substantive financial data and analysis for a period shorter than a full fiscal year. The document is not merely an announcement or a certification but a full quarterly financial report. Therefore, the correct classification is IR with high confidence. Q1 2018
2017-10-23 English
Notice of Annual General Meeting / Proxy Form 13 pages 488.5KB
AGM Information Classification · 100% confidence The document is titled 'Notice of Annual General Meeting 2 November 2017 and Explanatory Statement' and includes detailed information about the AGM such as date, location, resolutions to be voted on, voting procedures, and explanatory notes on each resolution. It references the financial report for the year ended 30 June 2017 but does not contain the financial report itself. The document is a notice and explanatory statement for the AGM, which is typical for AGM Information filings. It includes agenda items like adoption of the remuneration report, re-election of directors, and approval of placement capacity, all standard for AGM notices. The document length is substantial (15,000 characters), consistent with a full AGM notice and explanatory statement. Therefore, the document is best classified as AGM Information (AGM-R).
2017-09-27 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.